Therapy of Canine Hyperlipidemia with Bezafibrate

V. De Marco, K. S.M. Noronha, T. C. Casado, E. R. Nakandakare, J. C. Florio, E. Z. Santos, Chen Gilor

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals: Forty-six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results: Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. Conclusions and Clinical Importance: Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.

Original languageEnglish (US)
JournalJournal of Veterinary Internal Medicine
DOIs
StateAccepted/In press - 2017

Fingerprint

Bezafibrate
hyperlipidemia
Hyperlipidemias
Canidae
Dogs
therapeutics
dogs
Triglycerides
triacylglycerols
Therapeutics
Cholesterol
cholesterol
Alanine Transaminase
alanine transaminase
Serum
Adrenocortical Hyperfunction
hyperadrenocorticism
hypertriglyceridemia
hypothyroidism
Hypertriglyceridemia

Keywords

  • Cholesterol
  • Hyperadrenocorticism
  • Peroxisome proliferator-activated receptor
  • Schnauzer
  • Triglyceride

ASJC Scopus subject areas

  • veterinary(all)

Cite this

De Marco, V., Noronha, K. S. M., Casado, T. C., Nakandakare, E. R., Florio, J. C., Santos, E. Z., & Gilor, C. (Accepted/In press). Therapy of Canine Hyperlipidemia with Bezafibrate. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.14701

Therapy of Canine Hyperlipidemia with Bezafibrate. / De Marco, V.; Noronha, K. S.M.; Casado, T. C.; Nakandakare, E. R.; Florio, J. C.; Santos, E. Z.; Gilor, Chen.

In: Journal of Veterinary Internal Medicine, 2017.

Research output: Contribution to journalArticle

De Marco, V, Noronha, KSM, Casado, TC, Nakandakare, ER, Florio, JC, Santos, EZ & Gilor, C 2017, 'Therapy of Canine Hyperlipidemia with Bezafibrate', Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.14701
De Marco V, Noronha KSM, Casado TC, Nakandakare ER, Florio JC, Santos EZ et al. Therapy of Canine Hyperlipidemia with Bezafibrate. Journal of Veterinary Internal Medicine. 2017. https://doi.org/10.1111/jvim.14701
De Marco, V. ; Noronha, K. S.M. ; Casado, T. C. ; Nakandakare, E. R. ; Florio, J. C. ; Santos, E. Z. ; Gilor, Chen. / Therapy of Canine Hyperlipidemia with Bezafibrate. In: Journal of Veterinary Internal Medicine. 2017.
@article{ce5b798e204245cbaa1f8ff94f87b90a,
title = "Therapy of Canine Hyperlipidemia with Bezafibrate",
abstract = "Background: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals: Forty-six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results: Sixteen dogs (34.8{\%}) had primary hyperlipidemia, and 30 dogs (65.2{\%}) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3{\%}, n = 19/46], chronic treatment with glucocorticoids [10.8{\%}, n = 5/46], and hypothyroidism [15.2{\%}, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3{\%}) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7{\%}). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. Conclusions and Clinical Importance: Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.",
keywords = "Cholesterol, Hyperadrenocorticism, Peroxisome proliferator-activated receptor, Schnauzer, Triglyceride",
author = "{De Marco}, V. and Noronha, {K. S.M.} and Casado, {T. C.} and Nakandakare, {E. R.} and Florio, {J. C.} and Santos, {E. Z.} and Chen Gilor",
year = "2017",
doi = "10.1111/jvim.14701",
language = "English (US)",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Therapy of Canine Hyperlipidemia with Bezafibrate

AU - De Marco, V.

AU - Noronha, K. S.M.

AU - Casado, T. C.

AU - Nakandakare, E. R.

AU - Florio, J. C.

AU - Santos, E. Z.

AU - Gilor, Chen

PY - 2017

Y1 - 2017

N2 - Background: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals: Forty-six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results: Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. Conclusions and Clinical Importance: Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.

AB - Background: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. Animals: Forty-six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). Methods: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. Results: Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. Conclusions and Clinical Importance: Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.

KW - Cholesterol

KW - Hyperadrenocorticism

KW - Peroxisome proliferator-activated receptor

KW - Schnauzer

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=85017454007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017454007&partnerID=8YFLogxK

U2 - 10.1111/jvim.14701

DO - 10.1111/jvim.14701

M3 - Article

C2 - 28382723

AN - SCOPUS:85017454007

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

ER -